Citations

Clear

2438 citation(s) found for "Ly, Amy".

Performance and Safety of the Extravascular Implantable Cardioverter Defibrillator Through Long-Term Follow-Up: Final Results From the Pivotal Study
Friedman, Paul A. , Murgatroyd, Francis , Boersma, Lucas V.A. , Manlucu, Jaimie , Knight, Bradley P. , Leclercq, Christophe , Amin, Anish K. , Birgersdotter‐Green, Ulrika , Chan, Joseph Yat Sun , Engel, Gregory , Carvajal, Ignacio Muñoz , Sagi, Venkata, Johansen, Jens Brock , Steinwender, Clemens , Hounshell, Troy , Abben, Richard, Thompson, Amy , Wiggenhorn, Christopher, Willey, Sarah, Investigators, on behalf of the Extravascular ICD Pivotal Study, Friedman, Paul A , Leclercq, Christophe , Merkely, Béla , Birgersdotter-Green, Ulrika Maria , Chan, Joseph Yat Sun , Biffi, Mauro , Knops, Reinoud Elwin , Muñoz Carvajal, Ignacio , Epstein, Laurence M , Johansen, Jens Brock , Sterliński, Maciej , Steinwender, Clemens , Hounshell, Troy , Abben, Richard , Thompson, Amy E , Crozier, Ian , Knight, Bradley P , Boersma, Lucas , Clémenty, Nicolas , Biffi, Mauro , Engel, Gregory, Epstein, Laurence M. , Zhang, Yan , Crozier, Ian , Investigators, on behalf of the Extravascular ICD Pivotal Study

Mayo Clinic

Circulation | September 27, 2024 | Volume: 151 | Issue: 4 | Pages: 322-332

10.1161/circulationaha.124.071795 | PMID 39327797 Get It

BACKGROUND: Substernal lead placement of the extravascular implantable cardioverter defibrillator (EV ICD) permits both defibrillation at thresholds similar to those seen with transvenous implantable cardioverter defibrillators and effective anti-tachycardia pacing (ATP) while avoiding the vasculature and associated complications. The global Pivotal study has shown the EV ICD system to be safe and effective through 6 months, but long-term experience has yet to be published. Our aim was to report the performance and safety of the EV ICD system throughout the study. METHODS: The EV ICD Pivotal study was a prospective, global, single-arm, premarket clinical study. Individuals with a Class I or IIa indication for a single-chamber implantable cardioverter defibrillator per guidelines were enrolled. Freedom from major system- or procedure-related complications and appropriate and inappropriate therapy rates were assessed through 3 years with the Kaplan-Meier method. ATP success was calculated from simple proportions. RESULTS: An implantation was attempted in 316 patients (25.3% female; 53.8±13.1 years of age; 81.6% primary prevention; left ventricular ejection fraction, 38.9±15.4%). Of 299 patients with a successful implantation, 24 experienced 82 spontaneous arrhythmic episodes that were appropriately treated with ATP only (38, 46.3%), shock only (34, 41.5%), or both (10, 12.2%) for a Kaplan-Meier–estimated rate of first any appropriate therapy of 9.2% at 3 years. ATP was successful in 77.1% (37/48) of episodes, and ATP use significantly increased from discharge to last follow-up visit ( P <0.0001). Shock therapy was successful in 100% (27/27) of discrete, spontaneous ventricular arrhythmias. The inappropriate shock rates at 1 and 3 years were 9.8% and 17.5%, respectively, with P-wave oversensing the predominant cause. No major intraprocedural complications were reported, and the estimated freedom from system- or procedure-related major complications was 91.9% at 1 year and 89.0% at 3 years. The most common major complications were lead dislodgement (10 events; n=9 patients, 2.8%), postoperative wound or device pocket infection (n=8, 2.5%), and device inappropriate shock delivery (n=4, 1.3%). Twenty-four system revisions were performed as a result of major complications related to the EV ICD system or procedure. CONCLUSIONS: From implantation to study completion, the EV ICD Pivotal study demonstrated that a single integrated system with an extravascular lead placed in the substernal space maintains high ATP success, effective defibrillation, and a consistent safety profile. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04060680.
Case Report of Friedreich's Ataxia and ALG1‐Related Biochemical Abnormalities in a Patient With Progressive Spastic Paraplegia
Quinlan, Aisling , Rodan, Lance H. , Barkoudah, Elizabeth, Tam, Amy , Saffari, Afshin , Shammas, Ibrahim , Ranatunga, Wasantha , Morava‐Kozicz, Eva, Oglesbee, Devin , Ebrahimi‐Fakhari, Darius , Srivastava, Siddharth , Rodan, Lance , Ebrahimi-Fakhari, Darius , Srivastava, Siddharth , Oglesbee, Devin , Berry, Gerald J.

Mayo Clinic

American Journal of Medical Genetics Part A | September 26, 2024 | Volume: 197 | Issue: 2 | Pages: No page available

10.1002/ajmg.a.63890 | PMID 39324476 Get It

ABSTRACTFrataxin is an evolutionarily conserved mitochondrial protein responsible for iron homeostasis and metabolism. A deficiency of frataxin (encoded by FXN) leads to Friedreich's ataxia (FRDA), a progressive disorder that affects both the central and peripheral nervous systems, most commonly via a pathogenic GAA trinucleotide expansion. In contrast, pathogenic variants in ALG1 in humans cause a form of congenital disorder of glycosylation. Here, we present a 15‐year‐old boy with a clinical presentation that raised concern for complex hereditary spastic paraplegia (HSP), with motor features including progressive spastic paraparesis, cervical dystonia, cerebellar dysfunction, and diminished lower extremity reflexes. The proband was initially found to have a novel compound heterozygous variant in ALG1 on exome sequencing, along with N‐glycan profiling revealing evidence of defective mannosylation and Western blot analysis demonstrating an 84% reduction in ALG1 expression. Although several of his clinical features could be explained by the ALG1 variant specifically or considered as part of the presentation of CDGs in general, there were additional phenotypes that suggested an alternative, or additional, genetic diagnosis. Subsequently, he was found to have biallelic pathogenic GAA repeat expansions in FXN on genome sequencing, leading to a diagnosis of FRDA. Given that FRDA explained all his clinical features, the ALG1 variant may have been a hypomorphic form and/or a biochemical phenotype. Our findings underscore the importance of considering FRDA as a differential diagnosis in cases of complex HSP and demonstrate the utility of unbiased genome sequencing approaches that include detection of trinucleotide repeat expansions for progressive motor disorders.
Gene-Specific Effects on Brain Volume and Cognition of TMEM106B in Frontotemporal Lobar Degeneration
Vandebergh, Marijne , Ramos, Eliana Marisa , Corriveau‐Lecavalier, Nick , Ramanan, Vijay K. , Kornak, John , Mester, Carly , Kolander, Tyler, Brushaber, Danielle , Staffaroni, Adam M. , Geschwind, Daniel H., Wolf, Amy , Kantarci, Kejal, Petrucelli, Leonard , Broeck, Marleen Van den , Wynants, Sarah , Baker, Matthew , Borrego‐Écija, Sergi , Barmada, Sami J. , Darby, R. Ryan , Domoto‐Reilly, Kimiko , Fields, Julie A. , Ghoshal, Nupur , Graff‐Radford, Neill R. , Grant, Ian , Huey, Edward D. , Kwan, Justin , Litvan, Irene , Masdeu, Joseph C. , Mendez, Mario F. , Onyike, Chiadi U. , Pascual, Belén , Pressman, Peter , Ritter, Aaron, Roberson, Erik D. , Snyder, Allison , Sullivan, Anna Campbell, Wint, Dylan , Heuer, Hilary W. , Forsberg, Leah K. , Boxer, Adam L. , Rosen, Howard J. , Rademakers, Rosa , Kantarci, Kejal , Brushaber, Danielle E, Wolf, Amy A, Gendron, Tania F , Van den Broeck, Marleen, Borrego-Écija, Sergi , Appleby, Brian , Barmada, Sami , Bozoki, Andrea C , Darby, Richard Ryan , Dickerson, Bradford Clark , Domoto-Reilly, Kimiko , Fields, Julie A , Galasko, Douglas , Ghoshal, Nupur , Honig, Lawrence S. , Hsiung, Gink-Yuek , Huey, Edward D , Irwin, David J , Knopman, David S. , Kwan, Justin Y., Léger, Gabriel C, Litvan, Irene , Onyike, Chiadi , Pascual, Belen , Pressman, Peter S, Roberson, Erik , Tartaglia, Maria Carmela , Wint, Dylan , Heuer, Hilary W , Forsberg, Leah K , Boxer, Adam , Rosen, Howard J , Boeve, Brad , Rademakers, Rosa , Kantarci, Kejal , Ramanan, Vijay K , Corriveau-Lecavalier, Nick , Snyder, Allison , Vandebergh, Marijne , Mester, Carly , Geschwind, Daniel H. , Gendron, Tania F. , Appleby, Brian S. , Clark, David, Galasko, Douglas , Hsiung, Ging‐Yuek Robin , Irwin, David J. , Knopman, David S. , Léger, Gabriel C. , Masdeu, Joseph C , Boeve, Bradley F.

Mayo Clinic

Neurology | September 25, 2024 | Volume: 103 | Issue: 8 | Pages: No page available

10.1212/wnl.0000000000209832 | PMID 39321401 Get It

Immediate Breast Reconstruction Outcomes in Patients with Prior Mantle and Whole Breast Irradiation
Mullen, Barbara , Mazroua, Muhammad S., Murphy, Brenna M., Boonipat, Thanapoom , Gao, Robert W. , Mrdutt, Mary M., Shumway, Dean A. , Vijayasekaran, Aparna , Mrdutt, Mary M , Degnim, Amy C.

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | September 24, 2024 | Volume: 12 | Issue: 9 | Pages: e6121

10.1097/gox.0000000000006121 | PMID 39318444 Get It

Background: Limited studies have detailed the risk of mastectomy with immediate breast reconstruction among women who previously received mantle field radiation. Methods: A single institution retrospective review from 2010 to 2020 of patients previously treated with mantle field radiation (MF-RT) and subsequent mastectomy with immediate breast reconstruction was performed. Patients with prior whole breast irradiation (WBI) were also included as a reference group. Demographic, comorbidity, and surgical factors were collected. The primary outcome was major complications, defined as those requiring reoperation, intravenous antibiotics, or debridement. Results: Fourteen patients with prior MF-RT (27 breasts) and 129 with prior WBI (132 breasts) underwent mastectomy with immediate reconstruction. Prior MF-RT patients were significantly younger (43.8 versus 57.5, P < 0.001) and had significantly lower body mass index (23.6 versus 26.8, P = 0.004) compared with prior WBI patients. Nipple-sparing mastectomy was significantly more common in the mantle than in the WBI patients (78.6% versus 35.9%, P = 0.03). Most (13, 92.9%) prior mantle patients underwent tissue expander/implant-based reconstruction. Three (21.4%) prior MF-RT patients had major complications at any point, but none required an alternative type of reconstruction. On multiple variable analysis, there was no significant difference in major complication risk among prior MF-RT versus WBI patients (HR 0.74, confidence interval 0.20–2.70, P = 0.74). Conclusion: Immediate tissue expander/implant-based reconstruction in prior MF-RT patients seems safe, with a complication risk similar to that of prior WBI patients.
A framework for translating tauopathy therapeutics: Drug discovery to clinical trials
Feldman, Howard , Cummings, Jeffrey L., Boxer, Adam L., Staffaroni, Adam M. , Knopman, David S., Territo, Paul R. , Arnold, Steven E. , Boeve, Bradley F., Dacks, Penny A. , Diaz, Kristophe , Ewen, Colin, González, María Isabel , Harris, Glenn A., Hoffman, Beth J., Martinez, Terina N. , Nisenbaum, Laura K., Palma, Jose‐Alberto , Quintana, Melanie , Rabinovici, Gil D. , Rohrer, Jonathan D. , Rosen, Howard J., Troyer, Matthew D. , Kim, Doo Yeon , Tanzi, Rudolph E. , Zetterberg, Henrik, Ziogas, Nick, May, Patrick C. , Rommel, Amy, Feldman, Howard H , Palma, Jose-Alberto , Rohrer, Jonathan D , Rabinovici, Gil D , Dacks, Penny , Boxer, Adam L. , Knopman, David S. , Rizzo, Stacey J. Sukoff , Ballard, Clive , Beher, Dirk , Boeve, Bradley F. , Fiske, Brian , McDade, Eric , Zetterberg, Henrik

Mayo Clinic

Alzheimer's & Dementia | September 24, 2024 | Volume: 20 | Issue: 11 | Pages: 8129-8152

10.1002/alz.14250 | PMID 39316411 Get It

AbstractThe tauopathies are defined by pathological tau protein aggregates within a spectrum of clinically heterogeneous neurodegenerative diseases. The primary tauopathies meet the definition of rare diseases in the United States. There is no approved treatment for primary tauopathies. In this context, designing the most efficient development programs to translate promising targets and treatments from preclinical studies to early‐phase clinical trials is vital. In September 2022, the Rainwater Charitable Foundation convened an international expert workshop focused on the translation of tauopathy therapeutics through early‐phase trials. Our report on the workshop recommends a framework for principled drug development and a companion lexicon to facilitate communication focusing on reproducibility and achieving common elements. Topics include the selection of targets, drugs, biomarkers, participants, and study designs. The maturation of pharmacodynamic biomarkers to demonstrate target engagement and surrogate disease biomarkers is a crucial unmet need.Highlights Experts provided a framework to translate therapeutics (discovery to clinical trials). Experts focused on the “5 Rights” (target, drug, biomarker, participants, trial). Current research on frontotemporal degeneration, progressive supranuclear palsy, and corticobasal syndrome therapeutics includes 32 trials (37% on biologics) Tau therapeutics are being tested in Alzheimer's disease; primary tauopathies have a large unmet need.
Abstract B028: Beyond the diagnosis: A town hall event to explore black men’s journey with prostate cancer and sexuality
Kaninjing, Ernie, Ghasemi, Parisa , Danker, Skyler, Morton, Daniel J. , Dwyer, Kathleen , Young, Mary Ellen , Odedina, Folakemi T., Siston, Amy, Cole, Perry , Beckford, Patrick , Reese, Donald , Montgomery, Everett , Odeleye, Roland , Ogunsanya, Motolani E. , Nyame, Yaw A. , Neil, Jordan M. , Alexander, Adam C. , Mitchell, Thomas J. , Kendzor, Darla E.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | September 21, 2024 | Volume: 33 | Issue: 9_Supplement | Pages: B028-B028

10.1158/1538-7755.disp24-b028 Get It

Abstract Introduction Prostate cancer (CaP) significantly impacts Black men, who face higher morbidity despite lower overall mortality. The disease and its treatments profoundly affect sexuality, relationships, and quality of life (QoL), necessitating robust support systems. Healthcare, spousal support, community involvement, and interactions with other survivors are crucial for enhancing survivors' self-esteem and daily functioning. Virtual town halls offer a platform to share trusted information and foster community support, overcoming geographic and structural barriers. This town hall event will explore Black CaP survivors' experiences, focusing on sexuality post-diagnosis and related medical and psychological needs. MethodsOn June 13, 2024, The University of Oklahoma and Stephenson Cancer Center will host the 5th town hall event (via Microsoft Teams) to address Black CaP survivors' sexual health concerns. Previous town halls averaged 70 attendees and covered various aspects of the CaP journey. This event will include storytelling and panel discussions, with presentations from two CaP survivors and their spouses on personal experiences and coping strategies. A urologic oncologist will discuss treatment advancements and early detection, while a clinical health psychologist will address psychological and emotional aspects of survivorship. Simultaneous watch parties will be held in Milledgeville, Georgia, and Dallas, Texas. Interactive Q&A sessions will allow participant engagement. Attendees will complete a post-event survey to assess the session's impact and collect clinical and sociodemographic data. Quantitative data will be analyzed using SPSS v28, and audio-recorded sessions will be transcribed and thematically analyzed using Nvivo. Results will be available by the end of June and presented at the conference. Expected Results Participants will gain a deeper understanding of the intersection between CaP and sexuality in Black men's health. Discussions will highlight the psychological impact of a cancer diagnosis, challenges in maintaining sexual health during and after treatment, and the role of mental health support. The town hall aims to emphasize the importance of a strong support system, providing valuable coping skills through shared experiences and expert insights. Topics will include the emotional and psychological impact of sexual health challenges, partner support, and the necessity of open communication with healthcare providers. The event seeks to improve CaP survivors' QoL by emphasizing continuous education and integrating sexual health into overall survivorship care. Conclusion This town hall event aims to bridge gaps in understanding and addressing Black CaP survivors' sexual health concerns. By fostering open dialogue and providing expert insights, we hope to improve these men's QoL and survivorship care, emphasizing mental health support, spousal support, and continuous education. Citation Format: Motolani Ogunsanya, Ernie Kaninjing, Parisa Ghasemi, Skyler Danker, Daniel Morton, Kathleen Dwyer, Mary Ellen Young, Folakemi T. Odedina, Yaw Nyame, Amy Siston, Jordan Neil, Adam C Alexander, Perry Cole, Patrick Beckford, Donald Reese, Thomas Mitchell, Everett Montgomery, Roland Odeleye, Darla E. Kendzor. Beyond the diagnosis: A town hall event to explore black men’s journey with prostate cancer and sexuality [abstract]. In: Proceedings of the 17th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2024 Sep 21-24; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2024;33(9 Suppl):Abstract nr B028.
Germline mutations in a G protein identify signaling cross-talk in T cells
Ham, Hyoungjun , Jing, Huie , Lamborn, Ian T. , Kober, M. , Anderson, David E. , Druey, Kirk M. , Mandl, Judith N. , Isidor, Bertrand , Freeman, Alexandra F. , Ganesan, Sundar , Karsak, Meliha , Mustillo, Peter , Teo, Juliana , Zolkipli‐Cunningham, Zarazuela , Lecoquierre, François , Schmid, Jana Pachlopnik , Kuhns, Douglas B. , Xu, Xuehua , Al–Herz, Waleed , Terhal, Paulien A., Muurinen, Mari , Barlogis, Vincent , Danielson, Jeffrey J. , Stewart, Helen , Rading, Sebastian, Keren, Boris , Pfundt, Rolph , Potocki, Lorraine , Olivier, Kenneth N., Faivre, Laurence , Wong, Melanie , Puel, Anne , Chou, Janet , Tusseau, Maud, Moutsopoulos, Niki M. , Matthews, Helen, Simons, Cas , Fink, Danielle , Kong, Heidi H. , Kabát, Juraj , Kim, Woo Sung , Bierhals, Tatjana , Meguro, Kazuyuki , Gu, Jingwen , Stoddard, Jennifer , Banos-Pinero, Benito, Slack, Maria A., Trivellin, Giampaolo , Mazel, Benoît , Li, Samuel T. , Watts, Val J. , Rodriguez-Quevedo, Maria F. , Bruel, Ange‐Line , Lehalle, Daphné , Torres, Daniel , Sullivan, Kathleen E. , Duffourd, Yannis, Similuk, Morgan , Blanc, Pierre , Jin, Tian, Geha, Raif S., Casanova, Jean‐Laurent , Mäkitie, Outi , Edery, Patrick , Germain, Ronald N. , Billadeau, Daniel D. , Zhang, Yu , Lenardo, Michael J. , Kober, Megan M , Koval, Alexey , Anderson, D Eric , Druey, Kirk M , Mandl, Judith N , Isidor, Bertrand , Ferreira, Carlos R , Freeman, Alexandra F , Karsak, Meliha , Mustillo, Peter J , Teo, Juliana , Chatron, Nicolas , Lecoquierre, Francois , Oler, Andrew J , Schmid, Jana Pachlopnik , Kuhns, Douglas B , Xu, Xuehua , Hauck, Fabian , Al-Herz, Waleed , Wagner, Matias , Terhal, Paulien A , Muurinen, Mari , Barlogis, Vincent , Loid, Petra , Keren, Boris , Pfundt, Rolph , Zarember, Kol A , Vill, Katharina , Olivier, Kenneth N , Lesca, Gaetan , Faivre, Laurence , Puel, Anne , Chou, Janet , Moutsopoulos, Niki M , Simons, Cas , Soldatos, Ariane , Masle-Farquhar, Etienne , Pittaluga, Stefania , Brink, Robert , Kong, Heidi H , Kabat, Juraj , Bierhals, Tatjana , Hsu, Amy P. , Gu, Jingwen , Trivellin, Giampaolo , Mazel, Benoît , Soomann, Maarja , Li, Samuel , Watts, Val J , Stratakis, Constantine A , Rodriguez-Quevedo, Maria F , Bruel, Ange-Line , Lipsanen-Nyman, Marita , Saultier, Paul , Lehalle, Daphne , Torres, Daniel , Barbarot, Sébastien , Neu, Axel , Similuk, Morgan N , McWalter, Kirsty , Blanc, Pierre , Bézieau, Stéphane , Geha, Raif S , Casanova, Jean Laurent , Makitie, Outi M , Edery, Patrick , Christodoulou, John , Germain, Ronald N , Goodnow, Christopher C , Sakmar, Thomas P , Billadeau, Daniel D , Kury, Sebastien , Katanaev, Vladimir L , Zhang, Yu , Lenardo, Michael J , Su, Helen C , Berchiche, Yamina A. , Wagner, Matias , Cruz, Phillip , Lesca, Gaëtan , Tusseau, Maud , Taft, Ryan J. , Pittaluga, Stefania , Baños-Piñero, Benito, Stratakis, Constantine A. , Jain, Rashmi, Bezieau, Stéphane , Jin, Tian , Kubisch, Christian , Küry, Sébastien , Su, Helen C.

Mayo Clinic

Science | September 19, 2024 | Volume: 385 | Issue: 6715 | Pages: No page available

10.1126/science.add8947 | PMID 39298586 Get It

Humans with monogenic inborn errors responsible for extreme disease phenotypes can reveal essential physiological pathways. We investigated germline mutations in GNAI2 , which encodes G αi2 , a key component in heterotrimeric G protein signal transduction usually thought to regulate adenylyl cyclase–mediated cyclic adenosine monophosphate (cAMP) production. Patients with activating G αi2 mutations had clinical presentations that included impaired immunity. Mutant G αi2 impaired cell migration and augmented responses to T cell receptor (TCR) stimulation. We found that mutant G αi2 influenced TCR signaling by sequestering the guanosine triphosphatase (GTPase)–activating protein RASA2, thereby promoting RAS activation and increasing downstream extracellular signal–regulated kinase (ERK)/mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K)–AKT S6 signaling to drive cellular growth and proliferation.
Roadmap to a Global Template for Implementation of Ototoxicity Management for Cancer Treatment
Fernandez, Katharine , Hoetink, Alex E. , Berndtson, Deborah, Clark, Khaya D. , Dreisbach, Laura , Grosnik, Amy, Jamis, Carmen, Lee, John , Liberman, Patrícia Helena Pecora, Milnes, Trisha, Meijer, Annelot J. M. , Ortiz, Candice E., Rooker, Jennessa , Heuvel-Eibrink, Mary M. van den, Brewer, Carmen C. , Poling, Gayla L. , Clark, Khaya , Konrad‐Martin, Dawn , Geller, James I. , Goffi-Gómez, María Valéria Schmidt , Knight, Kristin R. , Lee, David S. , Sanchez, Victoria A , Heuvel‐Eibrink, Mary M. van den

Mayo Clinic

Ear & Hearing | September 12, 2024 | Volume: 46 | Issue: 2 | Pages: 286-297

10.1097/aud.0000000000001592 | PMID 39261989 Get It

Ototoxicity is among the adverse events related to cancer treatment that can have far-reaching consequences and negative impacts on quality-of-life for cancer patients and survivors of all ages. Ototoxicity management (OtoM) comprises the prevention, diagnosis, monitoring, and treatment, including rehabilitation and therapeutic intervention, of individuals who experience hearing loss, tinnitus, or balance/vestibular difficulties following exposures to ototoxic agents, including platinum chemotherapy (cisplatin, carboplatin) and cranial radiation. Despite the well-established physical, socioeconomic, and psychological consequences of hearing and balance dysfunction, there are no widely adopted standards for clinical management of cancer treatment-related ototoxicity. Consensus recommendations and a roadmap are needed to guide development of effective and feasible OtoM programs, direct research efforts, address the needs of caregivers and patients at all stages of cancer care and survivorship. Here we review current evidence and propose near-term to longer-term goals to advance OtoM in five strategic areas: (1) beneficiary awareness, empowerment, and engagement, (2) workforce enhancement, (3) program development, (4) policy, funding, and sustainability, and (5) research and evaluation. The goal is to identify needs and establish a roadmap to guide worldwide adoption of standardized OtoM for cancer treatment and improved outcomes for patients and survivors.
Development of a Breast Cancer Risk Prediction Model Integrating Monogenic, Polygenic, and Epidemiologic Risk
Kalia, Sarah S. , Boddicker, Nicholas , Yadav, Siddhartha , Huang, Hongyan , Na, Jie , Ambrosone, Christine B. , Yao, Song , Haiman, Christopher A. , Chen, Fei , John, Esther M. , Kurian, Allison W. , Guo, Boya , Lindström, Sara , Auer, Paul L. , Taylor, Jack A. , Hodge, James M. , Lori, Adriana , Bodelón, Clara , Vachon, Celine M. , Goldgar, David E. , Nathanson, Katherine L. , Weitzel, Jeffrey N. , Boddicker, Nicholas J , Hu, Chunling , Ambrosone, Christine B , Yao, Song , Haiman, Christopher A , Chen, Fei , John, Esther M , Kurian, Allison W , Guo, Boya , Lindstrom, Sara , Auer, Paul , Lacey, James V. , Neuhausen, Susan L. , Martı́nez, Marı́a Elena , Sandler, Dale P , O'Brien, Katie M , Taylor, Jack A , Teras, Lauren R , Hodge, James M , Lori, Adriana , Bodelon, Clara , Trentham-Dietz, Amy , Burnside, Elizabeth S , Vachon, Celine M. , Winham, Stacey J , Goldgar, David E , Domchek, Susan M , Nathanson, Katherine L , Weitzel, Jeffrey N , Couch, Fergus J. , Kraft, Peter , Yadav, Siddhartha , Na, Jie , Hu, Chunling , Sandler, Dale P. , O’Brien, Katie M. , Teras, Lauren R. , Trentham‐Dietz, Amy , Burnside, Elizabeth S. , Winham, Stacey J. , Domchek, Susan M. , Couch, Fergus J. , Kraft, Peter

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | September 11, 2024 | Volume: 33 | Issue: 11 | Pages: 1490-1499

10.1158/1055-9965.epi-24-0594 | PMID 39259185 Get It

Abstract Background: Breast cancer has been associated with monogenic, polygenic, and epidemiologic (clinical, reproductive, and lifestyle) risk factors, but studies evaluating the combined effects of these factors have been limited. Methods: We extended previous work in breast cancer risk modeling, incorporating pathogenic variants (PV) in six breast cancer predisposition genes and a 105-SNP polygenic risk score (PRS), to include an epidemiologic risk score (ERS) in a sample of non-Hispanic White women drawn from prospective cohorts and population-based case–control studies, with 23,518 cases and 22,832 controls, from the Cancer Risk Estimates Related to Susceptibility (CARRIERS) Consortium. Results: The model predicts 4.4-fold higher risk of breast cancer for postmenopausal women with no predisposition PV and median PRS, but with the highest versus lowest ERS. Overall, women with CHEK2 PVs had &gt;20% lifetime risk of breast cancer. However, 15.6% of women with CHEK2 PVs and a family history of breast cancer, and 45.1% of women with CHEK2 PVs but without a family history of breast cancer, had low (&lt;20%) predicted lifetime risk and thus were below the threshold for MRI screening. CHEK2 PV carriers at the 10th percentile of the joint distribution of ERS and PRS, without a family history of breast cancer, had a predicted lifetime risk similar to the general population. Conclusions: These results illustrate that an ERS, alone and combined with the PRS, can contribute to clinically relevant risk stratification. Impact: Integrating monogenic, polygenic, and epidemiologic risk factors in breast cancer risk prediction models may inform personalized screening and prevention efforts.
Leiomyosarcomas of the Visceral Adnexal and Uterine Ligaments and Adnexal Connective Tissue: Immunohistochemical, Molecular Genetic, and MDM2 Fluorescence In Situ Hybridization Analysis
Dashti, Nooshin K. , Swanson, Amy A. , Patel, Vatsal, Xing, Deyin , Feely, Michael, Keeney, Gary L., Gupta, Sounak , Schoolmeester, J. Kenneth

Mayo Clinic

International Journal of Gynecological Pathology | September 4, 2024 | Volume: 44 | Issue: 4 | Pages: 355-357

10.1097/pgp.0000000000001064 | PMID 39230557 Get It